Akorn sees FY13 adjusted EPS 57c-61c, consensus 66c Sees FY13 revenue $325M-$335M, consensus $330.73M. The company's guidance excludes the impact from any products for which the company has not yet received FDA approval.
Akorn initiated with Outperform, $50 target at William Blair William Blair started shares of Akorn with an Outperform rating and $50 price target. The firm says the maker of ophthalmic and hospital-based injectable therapies is one of the fastest-growing companies in the specialty pharmaceuticals sector. William Blair thinks consolidation will likely continue within the specialty/generics market and feels Akorn represents an attractive asset. The stock closed yesterday up 38c to $39.75.